Fast Five Quiz: Chronic Lymphocytic Leukemia (CLL) Treatment

Karl J. D'Silva, MD; Christina Poh, MD


November 02, 2021

BTK inhibitors ibrutinib or acalabrutinib, and the BCL-2 inhibitor venetoclax, in combination with the humanized anti-CD20 monoclonal antibody obinutuzumab, are recommended treatment options for patients with previously untreated CLL regardless of del(17p) or TP53 mutation status.

Learn more about treatment options.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.